Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004

Breast Cancer Research and Treatment

Volumn 120, Issue 1, 2010, Pages 217-227

  Brown, Monica ^a,b   Bauer, Katrina ^a   Pare, Mary ^c  

^a PUBLIC HEALTH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Sutter Medical Center   (United States)

Author keywords

Breast cancer; Cancer epidemiology; Triple negative breast cancer; Tumor markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER REGISTRY; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SECOND CANCER; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CALIFORNIA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 74849124623     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0469-z     Document Type: Article

References (80)

1. American Cancer Society (2008) California Facts, Figs 2008. California Division and Public Health Institute, California Cancer Registry, Oakland, CA
2. EA Healey EF Cook EJ Orav SJ Schnitt JL Connolly JR Harris 1993 Contralateral breast cancer: clinical characteristics and impact on prognosis J Clin Oncol 11 1545 1552 1:STN:280:DyaK3szivFCquw%3D%3D 8336193
3. HM Verkooijen V Chatelain G Fioretta G Vlastos E Rapiti AP Sappino C Bouchardy PO Chappuis 2007 Survival after bilateral breast cancer: results from a population-based study Breast Cancer Res Treat 105 347 357 10.1007/s10549-006-9455-x 10.1007/s10549-006-9455-x 17186359 (Pubitemid 47596444)
4. J Kollias IO Ellis CW Elston RW Blamey 2001 Prognostic significance of synchronous and metachronous bilateral breast cancer World J Surg 25 1117 1124 1:STN:280:DC%2BD3MrisFaqsQ%3D%3D 11571945
5. M Hartman K Czene M Reilly J Adolfsson J Bergh HO Adami PW Dickman P Hall 2007 Incidence and prognosis of synchronous and metachronous bilateral breast cancer J Clin Oncol 25 4210 4216 10.1200/JCO.2006.10.5056 10.1200/JCO.2006.10. 5056 17878475 (Pubitemid 47548560)
6. M Michowitz S Noy N Lazebnik D Aladjem 1985 Bilateral breast cancer J Surg Oncol 30 109 112 10.1002/jso.2930300210 10.1002/jso.2930300210 1:STN:280:DyaL28%2FptVGmsg%3D%3D 4079423 (Pubitemid 16226334)
7. DE Heron LT Komarnicky T Hyslop GF Schwartz CM Mansfield 2000 Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease Cancer 88 2739 2750 10.1002/1097-0142(20000615)88: 12<2739::AID-CNCR12>3.0.CO;2-J 10.1002/1097-0142(20000615)88:12<2739:: AID-CNCR12>3.0.CO;2-J 1:STN:280:DC%2BD3czivFymtw%3D%3D 10870056 (Pubitemid 30417934)
8. H Takahashi K Watanabe M Takahashi K Taguchi F Sasaki S Todo 2005 The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer Breast Cancer 12 196 202 10.2325/jbcs.12.196 10.2325/jbcs.12.196 16110289
9. JL Bernstein RH Lapinski SS Thakore JT Doucette WD Thompson 2003 The descriptive epidemiology of second primary breast cancer Epidemiology 14 552 558 10.1097/01.ede.0000072105.39021.6d 10.1097/01.ede.0000072105.39021.6d 14501270 (Pubitemid 40417036)
10. J Gogas C Markopoulos P Skandalakis H Gogas 1993 Bilateral breast cancer Am Surg 59 733 735 1:STN:280:DyaK2c%2FlslOgtw%3D%3D 8239195
11. P Broet A de la Rochefordiere SM Scholl A Fourquet V Mosseri JC Durand P Pouillart B Asselain 1995 Contralateral breast cancer: annual incidence and risk parameters J Clin Oncol 13 1578 1583 1:STN:280:DyaK2MzisFyksQ%3D%3D 7602346
12. Schaapveld M, Visser O, Louwman WJ, Willemse PHB, de Vries EGE, van der Graaf WTA, Otter R, Coebergh JWW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189-197
13. K Engin 1994 Prognostic factors in bilateral breast cancer Neoplasma 41 353 357 1:STN:280:DyaK2M7nsV2gsQ%3D%3D 7870220
14. J Kollias IO Ellis CW Elston RW Blamey 1999 Clinical and histological predictors of contralateral breast cancer Eur J Surg Oncol 25 584 589 10.1053/ejso.1999.0711 10.1053/ejso.1999.0711 1:STN:280:DC%2BD3c%2Fis1WjtQ%3D%3D 10556004
15. JL Bernstein WD Thompson N Risch TR Holford 1992 The genetic epidemiology of second primary breast cancer Am J Epidemiol 136 937 948 1:STN:280: DyaK3s%2FovFehsA%3D%3D 1456270
16. WH Kuo AM Yen PH Lee MF Hou SC Chen KM Chen TH Chen KJ Chang 2006 Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan Breast Cancer Res Treat 99 221 228 10.1007/s10549-006-9194-z 10.1007/s10549-006-9194-z 16544057 (Pubitemid 44268271)
17. LA Newman AA Sahin JE Cunningham ML Bondy NQ Mirza GS Vlastos GJ Whitman H Brown TA Buchholz MH Lee, et al. 2001 A case-control study of unilateral and bilateral breast carcinoma patients Cancer 91 1845 1853 10.1002/1097- 0142(20010515)91:10<1845::AID-CNCR1205>3.0.CO;2-Z 10.1002/1097- 0142(20010515)91:10<1845::AID-CNCR1205>3.0.CO;2-Z 1:STN:280: DC%2BD3M3ltVKnsQ%3D%3D 11346865 (Pubitemid 32424110)
18. AG Schwartz NE Ragheb GM Swanson WA Satariano 1989 Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis Breast Cancer Res Treat 14 245 254 10.1007/BF01810741 10.1007/BF01810741 1:STN:280:DyaK3c7gsFOlsQ%3D%3D 2605351 (Pubitemid 20001937)
19. TJ Yeatman GH Lyman SK Smith DS Reintgen AB Cantor CE Cox 1997 Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment Ann Surg Oncol 4 198 202 10.1007/BF02306610 10.1007/BF02306610 1:STN:280:DyaK2s3oslartQ%3D%3D 9142379
20. JL Bernstein WD Thompson N Risch TR Holford 1992 Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer Am J Epidemiol 136 925 936 1:STN:280: DyaK3s%2FovFehsw%3D%3D 1456269
21. X Gao SG Fisher B Emami 2003 Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study Int J Radiat Oncol Biol Phys 56 1038 1045 10.1016/S0360-3016(03)00203-7 10.1016/S0360-3016(03)00203-7 12829139 (Pubitemid 36794035)
22. E Berte AU Buzdar TL Smith GN Hortobagyi 1988 Bilateral primary breast cancer in patients treated with adjuvant therapy Am J Clin Oncol 11 114 118 1:STN:280:DyaL1c7ptFOrtg%3D%3D 3128945
23. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10.1038/35021093 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10963602 (Pubitemid 30671230)
24. LA Carey CM Perou CA Livasy LG Dressler D Cowan K Conway G Karaca MA Troester CK Tse S Edmiston, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 10.1001/jama.295.21.2492 10.1001/jama.295.21.2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D 16757721 (Pubitemid 43854964)
25. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 1721 1728 10.1002/cncr.22618 10.1002/cncr.22618 17387718 (Pubitemid 46668532)
26. M Brown A Tsodikov KR Bauer CA Parise V Caggiano 2008 The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004 Cancer 112 737 747 10.1002/cncr.23243 10.1002/cncr.23243 18189290 (Pubitemid 351240567)
27. M Intra N Rotmensz G Viale L Mariani B Bonanni MG Mastropasqua V Galimberti R Gennari P Veronesi M Colleoni, et al. 2004 Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution Cancer 101 905 912 10.1002/cncr.20452 10.1002/cncr.20452 15329896 (Pubitemid 39100421)
28. K Matsuo T Fukutomi H Tsuda S Akashi-Tanaka C Shimizu T Hasegawa 2001 Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma J Surg Oncol 77 31 34 10.1002/jso.1062 10.1002/jso.1062 1:STN:280:DC%2BD3M3ktFCnsw%3D%3D 11344480 (Pubitemid 32382016)
29. AM Geiger SS Thwin TL Lash DS Buist MN Prout F Wei TS Field M Ulcickas Yood FJ Frost SM Enger, et al. 2007 Recurrences and second primary breast cancers in older women with initial early-stage disease Cancer 109 966 974 10.1002/cncr.22472 10.1002/cncr.22472 17243096 (Pubitemid 46333538)
30. D Coradini S Oriana L Mariani R Miceli G Bresciani E Marubini G Di Fronzo 1998 Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 34 825 830 10.1016/S0959-8049(97)10121-6 10.1016/S0959-8049(97)10121-6 1:STN:280: DyaK1M%2FhsVChtQ%3D%3D 9797693 (Pubitemid 28248492)
31. AP Feinberg R Ohlsson S Henikoff 2006 The epigenetic progenitor origin of human cancer Nat Rev Genet 7 21 33 10.1038/nrg1748 10.1038/nrg1748 1:CAS:528:DC%2BD2MXhtlanu73E 16369569 (Pubitemid 41828945)
32. Zangwill M (2006) Eight years after its approval, Herceptin emerges as the best weapon against HER2-positive breast cancer. Cure 5
33. Fritz AG (2000) International classification of diseases for oncology: ICD-O, 3rd edn. World Health Organization, Geneva
34. Cancer reporting in California: standards for automated reporting (2006) California cancer reporting system standards, volume II. In: Sacramento: California Department of Health Services, Cancer Surveillance Section
35. Johnson CH, Adamo M (eds) (2007) The SEER program coding manual 2007. National Cancer Institute, Bethesda
36. Cancer reporting in California abstracting and coding procedures for hospitals (2007). California cancer reporting system standards, volume I. In: Sacramento: California Department of Health Services, Cancer Surveillance and Research Branch
37. KR Bauer M Brown C Creech NC Schlag V Caggiano 2007 Data quality assessment of HER2 in the Sacramento Region of the California Cancer Registry J Regist Manag 34 4 7
38. SL Stewart KC Swallen SL Glaser PL Horn-Ross DW West 1999 Comparison of methods for classifying Hispanic ethnicity in a population-based cancer registry Am J Epidemiol 149 1063 1071 1:STN:280:DyaK1M3otFGitg%3D%3D 10355383
39. K Yost C Perkins R Cohen C Morris W Wright 2001 Socioeconomic status and breast cancer incidence in California for different race/ethnic groups Cancer Causes Control 12 703 711 10.1023/A:1011240019516 10.1023/A:1011240019516 1:STN:280:DC%2BD3MrhsVantw%3D%3D 11562110 (Pubitemid 32803497)
40. Rural Urban Commuting Area Code In: US Department of Agriculture Economic Research Service, 2001, Washington, DC, vol. 2004; 2006
41. The use of RUCAS (version 2.0) in health care ( http://depts.washington. edu/uwruca/uses.html )
42. Greene FL, American Joint Committee on Cancer, American Cancer Society (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York
43. SEER Extent of Disease (1998) Codes and coding instructions, 3rd edn. National Cancer Institute, National Institutes of Health, Bethesda
44. Collaborative Staging Task Force of the American Joint Committee on Cancer (2004) Collaborative staging manual and coding instructions, version 01.03.00. Jointly published by American Joint Committee on Cancer and U.S. Department of Health and Human Services, Chicago and Bethesda
45. Fleiss JL, Levin BA, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. Wiley, Hoboken
46. JR Landis GG Koch 1977 The measurement of observer agreement for categorical data Biometrics 33 159 174 10.2307/2529310 10.2307/2529310 1:STN:280:DyaE2s7jsFWqtA%3D%3D 843571
47. LC Collins SJ Schnitt GA Colditz AC Deitz HJ Baer WY Chen JL Connolly M Rubin Y Fu B Rosner, et al. 2006 Risk factors for luminal, HER2, and basal-like breast cancer subtypes: results from a tissue microarray-based analysis of invasive breast cancers from women enrolled in the nurses' health study Breast Cancer Res Treat 100 S275 Abstract 5041
48. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 10.1158/1078-0432.CCR-06-1109 10.1158/1078-0432.CCR-06-1109 1:CAS:528: DC%2BD2sXkt1enur0%3D 17438091 (Pubitemid 46698581)
49. SP Kang M Martel LN Harris 2008 Triple negative breast cancer: current understanding of biology and treatment options Curr Opin Obstet Gynecol 20 40 46 10.1097/GCO.0b013e3282f40de9 10.1097/GCO.0b013e3282f40de9 18197004
50. JM Allan LB Travis 2005 Mechanisms of therapy-related carcinogenesis Nat Rev Cancer 5 943 955 10.1038/nrc1749 10.1038/nrc1749 1:CAS:528: DC%2BD2MXht1ykurbJ 16294218 (Pubitemid 41781694)
51. D Amadori S Ronconi 2005 Secondary lung tumors in hematological patients Semin Respir Crit Care Med 26 520 526 10.1055/s-2005-922035 10.1055/s-2005- 922035 16267703 (Pubitemid 41552381)
52. M Abramovitz B Leyland-Jones 2007 Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment Cancer Genomics Proteomics 4 135 145 1:CAS:528:DC%2BD2sXls1GrtLk%3D 17878517
53. G Tonon 2008 From oncogene to network addiction: the new frontier of cancer genomics and therapeutics Future Oncol 4 569 577 10.2217/14796694.4.4.569 10.2217/14796694.4.4.569 1:CAS:528:DC%2BD1cXpsFKqtL0%3D 18684067
54. JN Weitzel M Robson B Pasini S Manoukian D Stoppa-Lyonnet HT Lynch J McLennan WD Foulkes T Wagner N Tung, et al. 2005 A comparison of bilateral breast cancers in BRCA carriers Cancer Epidemiol Biomarkers Prev 14 1534 1538 10.1158/1055-9965.EPI-05-0070 10.1158/1055-9965.EPI-05-0070 1:CAS:528: DC%2BD2MXkvVCkur8%3D 15941968 (Pubitemid 40807358)
55. CS Cooney NF Khouri TN Tsangaris 2008 The role of breast MRI in the management of patients with breast disease Adv Surg 42 299 312 10.1016/j.yasu.2008.03.003 10.1016/j.yasu.2008.03.003 18953825
56. SC Partridge 2008 Future applications and innovations of clinical breast magnetic resonance imaging Top Magn Reson Imaging 19 171 176 10.1097/RMR.0b013e31818a4090 10.1097/RMR.0b013e31818a4090 18941397
57. E Warner 2008 The role of magnetic resonance imaging in screening women at high risk of breast cancer Top Magn Reson Imaging 19 163 169 10.1097/RMR.0b013e31818bc994 10.1097/RMR.0b013e31818bc994 18941396
58. MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol May 20 suppl, abstract 1000
59. Broglio K, Moulder SL, Hsu L, Kau S, Pusztai L, Symmans WF, Hortobagyi GN, Gonzalez-Angulo AM, Liedtke C (2008) Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. J Clin Oncol May 20 suppl, abstract 1001
60. CJ Creighton S Massarweh S Huang A Tsimelzon SG Hilsenbeck CK Osborne J Shou L Malorni R Schiff 2008 Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts Cancer Res 68 7493 7501 10.1158/0008-5472.CAN-08-1404 10.1158/0008-5472.CAN-08-1404 1:CAS:528:DC%2BD1cXhtFWltb7F 18794137
61. S Dawood E Resetkova AM Gonzalez-Angulo 2008 Trastuzumab administration associated with change in HER2 status Clin Breast Cancer 8 366 369 10.3816/CBC.2008.n.044 10.3816/CBC.2008.n.044 18757266
62. KS Asgeirsson A Agrawal C Allen A Hitch IO Ellis C Chapman KL Cheung JF Robertson 2007 Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients Breast Cancer Res 9 R75 10.1186/bcr1788 10.1186/bcr1788 17976236
63. C Tapia S Savic U Wagner R Schonegg H Novotny B Grilli M Herzog AD Barascud I Zlobec G Cathomas, et al. 2007 HER2 gene status in primary breast cancers and matched distant metastases Breast Cancer Res 9 R31 10.1186/bcr1676 10.1186/bcr1676 17511881 (Pubitemid 350215176)
64. Z Varga R Caduff B Pestalozzi 2005 Stability of the HER2 gene after primary chemotherapy in advanced breast cancer Virchows Arch 446 136 141 10.1007/s00428-004-1164-4 10.1007/s00428-004-1164-4 1:CAS:528: DC%2BD2MXhs1yhu7o%3D 15650840 (Pubitemid 40385643)
65. DW Felsher 2008 Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 68 3081 3086 10.1158/0008-5472.CAN-07-5832 10.1158/0008-5472.CAN-07-5832 1:CAS:528:DC%2BD1cXltlSmtrc%3D 18451131 discussion 3086
66. A Thor 2001 HER2-a discussion of testing approaches in the USA Ann Oncol 12 Suppl 1 S101 S107 10.1023/A:1011120309910 10.1023/A:1011120309910 11521714
67. RW Carlson SJ Moench ME Hammond EA Perez HJ Burstein DC Allred CL Vogel LJ Goldstein G Somlo WJ Gradishar, et al. 2006 HER2 testing in breast cancer: NCCN Task Force report and recommendations J Natl Compr Cancer Netw 4 Suppl 3 S1 S22 quiz S23-S24
68. CI Li KE Malone PL Porter NS Weiss MT Tang JR Daling 2003 The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65-79 years of age Cancer Epidemiol Biomarkers Prev 12 1061 1066 1:CAS:528:DC%2BD3sXosVCru7Y%3D 14578143
69. AM Fair K Montgomery 2009 Energy balance, physical activity, and cancer risk Methods Mol Biol 472 57 88 10.1007/978-1-60327-492-0-3 10.1007/978-1-60327- 492-0-3 19107429
70. JJ Dignam K Wieand KA Johnson B Fisher L Xu EP Mamounas 2003 Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer J Natl Cancer Inst 95 1467 1476 1:CAS:528:DC%2BD3sXnvVCjtrs%3D 14519753
71. Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97:519-526, 529. quiz 527-518. doi: 10.1016/S0002-8223(97)00133-8
72. Parise C, Caggiano V, Brown M, Bauer K (2008) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. The Breast Journal in publication
73. CI Li JR Daling KE Malone 2003 Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998 J Clin Oncol 21 28 34 10.1200/JCO.2003.03.088 10.1200/JCO.2003.03.088 1:CAS:528:DC%2BD38XpvVWntrg%3D 12506166
74. VR Grann AB Troxel NJ Zojwalla JS Jacobson D Hershman AI Neugut 2005 Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma Cancer 103 2241 2251 10.1002/cncr.21030 10.1002/cncr.21030 1:CAS:528:DC%2BD2MXlsFSnt78%3D 15844176 (Pubitemid 40686567)
75. LK Dunnwald MA Rossing CI Li 2007 Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients Breast Cancer Res 9 R6 10.1186/bcr1639 10.1186/bcr1639 17239243 (Pubitemid 350215155)
76. RD Cress AM Zaslavsky DW West RE Wolf MC Felter JZ Ayanian 2003 Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries Med Care 41 1006 1012 10.1097/01.MLR. 0000083740.12949.88 10.1097/01.MLR.0000083740.12949.88 12972840
77. JL Malin KL Kahn J Adams L Kwan M Laouri PA Ganz 2002 Validity of cancer registry data for measuring the quality of breast cancer care J Natl Cancer Inst 94 835 844 12048271 (Pubitemid 34705055)
78. E Matros ZC Wang G Lodeiro A Miron JD Iglehart AL Richardson 2005 BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles Breast Cancer Res Treat 91 179 186 10.1007/s10549-004-7603-8 10.1007/s10549-004-7603-8 1:CAS:528:DC%2BD2MXjvVWjsro%3D 15868446 (Pubitemid 40684930)
79. A Ribeiro-Silva LN Ramalho SB Garcia DF Brandao F Chahud S Zucoloto 2005 p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer Histopathology 47 458 466 10.1111/j.1365-2559.2005.02249.x 10.1111/j.1365-2559. 2005.02249.x 1:STN:280:DC%2BD2MrmsFKksg%3D%3D 16241993 (Pubitemid 41626723)
80. L De Maeyer E Van Limbergen K De Nys P Moerman N Pochet W Hendrickx H Wildiers R Paridaens A Smeets MR Christiaens, et al. 2008 Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 26 335 336 10.1200/JCO.2007.14.8411 10.1200/JCO.2007.14.8411 18182677 author reply 336-338